BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 34621020)

  • 1. E3 ubiquitin ligase Atrogin-1 mediates adaptive resistance to KIT-targeted inhibition in gastrointestinal stromal tumor.
    García-Valverde A; Rosell J; Sayols S; Gómez-Peregrina D; Pilco-Janeta DF; Olivares-Rivas I; de Álava E; Maurel J; Rubió-Casadevall J; Esteve A; Gut M; Valverde C; Barretina J; Carles J; Demetri GD; Fletcher JA; Arribas J; Serrano C
    Oncogene; 2021 Dec; 40(48):6614-6626. PubMed ID: 34621020
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual Targeting of Insulin Receptor and KIT in Imatinib-Resistant Gastrointestinal Stromal Tumors.
    Chen W; Kuang Y; Qiu HB; Cao Z; Tu Y; Sheng Q; Eilers G; He Q; Li HL; Zhu M; Wang Y; Zhang R; Wu Y; Meng F; Fletcher JA; Ou WB
    Cancer Res; 2017 Sep; 77(18):5107-5117. PubMed ID: 28760855
    [TBL] [Abstract][Full Text] [Related]  

  • 3. KIT
    Banerjee S; Yoon H; Ting S; Tang CM; Yebra M; Wenzel AT; Yeerna H; Mesirov JP; Wechsler-Reya RJ; Tamayo P; Sicklick JK
    Mol Cancer Ther; 2021 Oct; 20(10):2035-2048. PubMed ID: 34376580
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical Activity of PI3K Inhibitor Copanlisib in Gastrointestinal Stromal Tumor.
    García-Valverde A; Rosell J; Serna G; Valverde C; Carles J; Nuciforo P; Fletcher JA; Arribas J; Politz O; Serrano C
    Mol Cancer Ther; 2020 Jun; 19(6):1289-1297. PubMed ID: 32371592
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological Inhibition of KIT Activates MET Signaling in Gastrointestinal Stromal Tumors.
    Cohen NA; Zeng S; Seifert AM; Kim TS; Sorenson EC; Greer JB; Beckman MJ; Santamaria-Barria JA; Crawley MH; Green BL; Rossi F; Besmer P; Antonescu CR; DeMatteo RP
    Cancer Res; 2015 May; 75(10):2061-70. PubMed ID: 25836719
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhancer Domains in Gastrointestinal Stromal Tumor Regulate KIT Expression and Are Targetable by BET Bromodomain Inhibition.
    Hemming ML; Lawlor MA; Andersen JL; Hagan T; Chipashvili O; Scott TG; Raut CP; Sicinska E; Armstrong SA; Demetri GD; Bradner JE
    Cancer Res; 2019 Mar; 79(5):994-1009. PubMed ID: 30630822
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting the WEE1 kinase strengthens the antitumor activity of imatinib via promoting KIT autophagic degradation in gastrointestinal stromal tumors.
    Liu W; Zeng X; Yin Y; Li C; Yang W; Wan W; Shi L; Wang G; Tao K; Zhang P
    Gastric Cancer; 2020 Jan; 23(1):39-51. PubMed ID: 31197522
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TAS-116 inhibits oncogenic KIT signalling on the Golgi in both imatinib-naïve and imatinib-resistant gastrointestinal stromal tumours.
    Saito Y; Takahashi T; Obata Y; Nishida T; Ohkubo S; Nakagawa F; Serada S; Fujimoto M; Ohkawara T; Nishigaki T; Sugase T; Koh M; Ishida T; Tanaka K; Miyazaki Y; Makino T; Kurokawa Y; Nakajima K; Yamasaki M; Hirota S; Naka T; Mori M; Doki Y
    Br J Cancer; 2020 Mar; 122(5):658-667. PubMed ID: 31857719
    [TBL] [Abstract][Full Text] [Related]  

  • 9. KIT over-expression by p55PIK-PI3K leads to Imatinib-resistance in patients with gastrointestinal stromal tumors.
    Lai S; Wang G; Cao X; Luo X; Wang G; Xia X; Hu J; Wang J
    Oncotarget; 2016 Jan; 7(2):1367-79. PubMed ID: 26587973
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RACK1 overexpression is linked to acquired imatinib resistance in gastrointestinal stromal tumor.
    Gao X; Xue A; Fang Y; Shu P; Ling J; Hou Y; Shen K; Qin J; Sun Y; Qin X
    Oncotarget; 2016 Mar; 7(12):14300-9. PubMed ID: 26893362
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role for the proapoptotic factor BIM in mediating imatinib-induced apoptosis in a c-KIT-dependent gastrointestinal stromal tumor cell line.
    Gordon PM; Fisher DE
    J Biol Chem; 2010 May; 285(19):14109-14. PubMed ID: 20231287
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Novel Receptor Tyrosine Kinase Switch Promotes Gastrointestinal Stromal Tumor Drug Resistance.
    Boichuk S; Galembikova A; Dunaev P; Valeeva E; Shagimardanova E; Gusev O; Khaiboullina S
    Molecules; 2017 Dec; 22(12):. PubMed ID: 29206199
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting of FGF-Signaling Re-Sensitizes Gastrointestinal Stromal Tumors (GIST) to Imatinib In Vitro and In Vivo.
    Boichuk S; Galembikova A; Dunaev P; Micheeva E; Valeeva E; Novikova M; Khromova N; Kopnin P
    Molecules; 2018 Oct; 23(10):. PubMed ID: 30326595
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of PI3K and MAPK pathways along with KIT inhibitors as a strategy to overcome drug resistance in gastrointestinal stromal tumors.
    Gupta A; Ma S; Che K; Pobbati AV; Rubin BP
    PLoS One; 2021; 16(7):e0252689. PubMed ID: 34324512
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Silencing of adaptor protein SH3BP2 reduces KIT/PDGFRA receptors expression and impairs gastrointestinal stromal tumors growth.
    Serrano-Candelas E; Ainsua-Enrich E; Navinés-Ferrer A; Rodrigues P; García-Valverde A; Bazzocco S; Macaya I; Arribas J; Serrano C; Sayós J; Arango D; Martin M
    Mol Oncol; 2018 Aug; 12(8):1383-1397. PubMed ID: 29885053
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hedgehog pathway dysregulation contributes to the pathogenesis of human gastrointestinal stromal tumors via GLI-mediated activation of KIT expression.
    Tang CM; Lee TE; Syed SA; Burgoyne AM; Leonard SY; Gao F; Chan JC; Shi E; Chmielecki J; Morosini D; Wang K; Ross JS; Kendrick ML; Bardsley MR; Siena M; Mao J; Harismendy O; Ordog T; Sicklick JK
    Oncotarget; 2016 Nov; 7(48):78226-78241. PubMed ID: 27793025
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Kitlow stem cells cause resistance to Kit/platelet-derived growth factor alpha inhibitors in murine gastrointestinal stromal tumors.
    Bardsley MR; Horváth VJ; Asuzu DT; Lorincz A; Redelman D; Hayashi Y; Popko LN; Young DL; Lomberk GA; Urrutia RA; Farrugia G; Rubin BP; Ordog T
    Gastroenterology; 2010 Sep; 139(3):942-52. PubMed ID: 20621681
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gastrointestinal stromal tumors.
    Antonescu C
    Curr Top Microbiol Immunol; 2012; 355():41-57. PubMed ID: 22015552
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination of Imatinib Mesylate and AKT Inhibitor Provides Synergistic Effects in Preclinical Study of Gastrointestinal Stromal Tumor.
    Zook P; Pathak HB; Belinsky MG; Gersz L; Devarajan K; Zhou Y; Godwin AK; von Mehren M; Rink L
    Clin Cancer Res; 2017 Jan; 23(1):171-180. PubMed ID: 27370604
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel receptor tyrosine kinase targeted combination therapies for imatinib-resistant gastrointestinal stromal tumors (GIST).
    Mahadevan D; Theiss N; Morales C; Stejskal AE; Cooke LS; Zhu M; Kurtzman D; Swart R; Ong E; Qi W
    Oncotarget; 2015 Feb; 6(4):1954-66. PubMed ID: 25557174
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.